Chemotherapeutic Toxicity Clinical Trial
Official title:
Second Affiliated Hospital Zhejiang University School of Medicine
Chemotherapy causes motor nerve dysfunction and degeneration that may alter the response to neuromuscular blocking drugs. To analyse the risk of residual neuromuscular block (RNMB) induced by rocuronium given in standard doses to patients who undergo chemotherapy within three months.
Status | Not yet recruiting |
Enrollment | 80 |
Est. completion date | August 31, 2022 |
Est. primary completion date | February 28, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Patients classified as American Society of Anesthesiology physical status (ASA PS) classes I, II or III - Aged between 18 and 70 years - Scheduled for radiofrequency ablation of liver tumours under general anaesthesia with an expected surgery duration shorter than 60min Exclusion Criteria: - Allergy to rocuronium - Myasthenia gravis - Guillain-Barre ยด syndrome - Duchenne muscular dystrophy or similar - Receiving drugs that might interfere with the neuromuscular transmission or the response to neuromuscular blockers, such as some anticonvulsants and antibiotics |
Country | Name | City | State |
---|---|---|---|
China | Huzhou Central Hospital | Huzhou | Zhejiang |
China | Quzhou People's Hospital | Quzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital, School of Medicine, Zhejiang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Clinical duration of muscle relaxation | Time interval from the completion of intravenous injection of rocuronium to 25% recovery of the first twitch in the TOF stimulation pattern | The first 90min following intravenous injection of rocuronium | |
Other | TOF ratio | Dividing the amplitude of the fourth response by the amplitude of the first response | 10min following intravenous injection of rocuronium | |
Other | T1 amplitude | The amplitude of the first twitch to TOF stimulation | 10min following intravenous injection of rocuronium | |
Other | TOF ratio | Dividing the amplitude of the fourth response by the amplitude of the first response | 20min following intravenous injection of rocuronium | |
Other | T1 amplitude | The amplitude of the first twitch to TOF stimulation | 20min following intravenous injection of rocuronium | |
Other | TOF ratio | Dividing the amplitude of the fourth response by the amplitude of the first response | 30min following intravenous injection of rocuronium | |
Other | T1 amplitude | The amplitude of the first twitch to TOF stimulation | 30min following intravenous injection of rocuronium | |
Other | TOF ratio | Dividing the amplitude of the fourth response by the amplitude of the first response | 40min following intravenous injection of rocuronium | |
Other | T1 amplitude | The amplitude of the first twitch to TOF stimulation | 40min following intravenous injection of rocuronium | |
Other | TOF ratio | Dividing the amplitude of the fourth response by the amplitude of the first response | 50min following intravenous injection of rocuronium | |
Other | T1 amplitude | The amplitude of the first twitch to TOF stimulation | 50min following intravenous injection of rocuronium | |
Other | TOF ratio | Dividing the amplitude of the fourth response by the amplitude of the first response | 60min following intravenous injection of rocuronium | |
Other | T1 amplitude | The amplitude of the first twitch to TOF stimulation | 60min following intravenous injection of rocuronium | |
Other | TOF ratio | Dividing the amplitude of the fourth response by the amplitude of the first response | 70min following intravenous injection of rocuronium | |
Other | T1 amplitude | The amplitude of the first twitch to TOF stimulation | 70min following intravenous injection of rocuronium | |
Other | TOF ratio | Dividing the amplitude of the fourth response by the amplitude of the first response | 80min following intravenous injection of rocuronium | |
Other | T1 amplitude | The amplitude of the first twitch to TOF stimulation | 80min following intravenous injection of rocuronium | |
Other | TOF ratio | Dividing the amplitude of the fourth response by the amplitude of the first response | 90min following intravenous injection of rocuronium | |
Other | T1 amplitude | The amplitude of the first twitch to TOF stimulation | 90min following intravenous injection of rocuronium | |
Primary | Muscle relaxation recovery index | Time interval from 25% recovery to 75% recovery of the first twitch in the TOF stimulation pattern | The first 90 min following intravenous injection of rocuronium | |
Secondary | Onset time of muscle relaxation | Time interval from the completion of intravenous injection of rocuronium to the maximal depression of the first twitch in the TOF stimulation pattern | The first 90 min following intravenous injection of rocuronium |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04277650 -
System for High-Intensity Evaluation During Radiotherapy
|
N/A | |
Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
Recruiting |
NCT06041477 -
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
|
Phase 3 | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Recruiting |
NCT06197581 -
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
|
N/A | |
Recruiting |
NCT06012253 -
The Effect of Home-Based Walking Program on Peripheral Neuropathy, Fatigue and Quality of Life
|
N/A | |
Completed |
NCT04843410 -
Effect of Exercise in the Management of Peripheral Neuropathy
|
N/A | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
Terminated |
NCT04607668 -
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
|
Phase 3 | |
Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A | |
Recruiting |
NCT06357871 -
Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
|
||
Completed |
NCT02996201 -
Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial
|
N/A | |
Completed |
NCT00292526 -
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
|
Phase 4 | |
Completed |
NCT04663178 -
Foot Bath and Chemotherapy Induced Fatigue
|
N/A | |
Recruiting |
NCT03191461 -
Myocardial Perfusion and Fibrosis in Cancer Survivors
|
||
Recruiting |
NCT05251922 -
Tolerance of Anti-Cancer Therapy in the Elderly
|
||
Not yet recruiting |
NCT06387901 -
Investigating Paclitaxel Toxicity in Breast Cancer: The Roles of Physical Activity and Body Composition.
|
||
Recruiting |
NCT05892146 -
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
|
N/A | |
Not yet recruiting |
NCT05921149 -
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
|
N/A | |
Recruiting |
NCT05302336 -
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
|
Phase 4 |